Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
AnaptysBio (NASDAQ: ANAB) has announced it will host an investor call and webcast on June 3, 2025 to present updated data from its global Phase 2b RENOIR clinical trial. The trial evaluates rosnilimab, a PD-1+ T cells depleter and agonist, for treating moderate-to-severe rheumatoid arthritis.
The presentation will feature distinguished speakers including Paul Emery, M.D. from the University of Leeds and Jonathan Graf, M.D. from UCSF. Following the data release, company executives led by CEO Daniel Faga will participate in two major investor conferences: the Jefferies Global Healthcare Conference on June 5 and the Goldman Sachs Global Healthcare Conference on June 11, 2025.
AnaptysBio (NASDAQ: ANAB) ha annunciato che terrà una conferenza telefonica e una webcast per gli investitori il 3 giugno 2025 per presentare dati aggiornati del suo studio clinico globale di Fase 2b RENOIR. Lo studio valuta rosnilimab, un depleter e agonista delle cellule T PD-1+, per il trattamento dell'artrite reumatoide da moderata a grave.
La presentazione vedrà la partecipazione di relatori di spicco, tra cui il dott. Paul Emery dell'Università di Leeds e il dott. Jonathan Graf della UCSF. Dopo la pubblicazione dei dati, i dirigenti dell'azienda, guidati dal CEO Daniel Faga, parteciperanno a due importanti conferenze per investitori: la Jefferies Global Healthcare Conference il 5 giugno e la Goldman Sachs Global Healthcare Conference l'11 giugno 2025.
AnaptysBio (NASDAQ: ANAB) ha anunciado que realizará una llamada y webcast para inversores el 3 de junio de 2025 para presentar datos actualizados de su ensayo clínico global de Fase 2b RENOIR. El estudio evalúa rosnilimab, un depletador y agonista de células T PD-1+, para el tratamiento de la artritis reumatoide moderada a grave.
La presentación contará con ponentes destacados, incluyendo al Dr. Paul Emery de la Universidad de Leeds y al Dr. Jonathan Graf de la UCSF. Tras la publicación de los datos, los ejecutivos de la empresa, liderados por el CEO Daniel Faga, participarán en dos importantes conferencias para inversores: la Jefferies Global Healthcare Conference el 5 de junio y la Goldman Sachs Global Healthcare Conference el 11 de junio de 2025.
AnaptysBio (NASDAQ: ANAB)는 2025년 6월 3일에 투자자 대상 콜 및 웹캐스트를 개최하여 글로벌 2b상 RENOIR 임상시험의 최신 데이터를 발표할 것이라고 밝혔습니다. 이 임상시험은 중등도에서 중증 류머티스 관절염 치료를 위한 PD-1+ T 세포 제거 및 작용제인 rosnilimab을 평가합니다.
발표에는 리즈 대학교의 Paul Emery 박사와 UCSF의 Jonathan Graf 박사 등 저명한 연사들이 참여할 예정입니다. 데이터 발표 후, CEO Daniel Faga가 이끄는 회사 경영진은 6월 5일 Jefferies Global Healthcare Conference와 6월 11일 Goldman Sachs Global Healthcare Conference 등 두 주요 투자자 컨퍼런스에 참석할 예정입니다.
AnaptysBio (NASDAQ : ANAB) a annoncé qu'elle tiendra une conférence téléphonique et un webcast pour les investisseurs le 3 juin 2025 afin de présenter des données mises à jour de son essai clinique mondial de phase 2b RENOIR. Cet essai évalue rosnilimab, un dépléteur et agoniste des cellules T PD-1+, pour le traitement de la polyarthrite rhumatoïde modérée à sévère.
La présentation comprendra des intervenants de renom, notamment le Dr Paul Emery de l'Université de Leeds et le Dr Jonathan Graf de l'UCSF. Après la publication des données, les dirigeants de l'entreprise, dirigés par le PDG Daniel Faga, participeront à deux grandes conférences pour investisseurs : la Jefferies Global Healthcare Conference le 5 juin et la Goldman Sachs Global Healthcare Conference le 11 juin 2025.
AnaptysBio (NASDAQ: ANAB) hat angekündigt, am 3. Juni 2025 einen Investorentelefonkonferenz und ein Webcast abzuhalten, um aktualisierte Daten aus der globalen Phase-2b-Studie RENOIR zu präsentieren. Die Studie bewertet rosnilimab, einen PD-1+ T-Zell-Depletor und Agonisten, zur Behandlung von mittelschwerer bis schwerer rheumatoider Arthritis.
Die Präsentation wird von renommierten Rednern begleitet, darunter Paul Emery, M.D. von der Universität Leeds und Jonathan Graf, M.D. von der UCSF. Nach der Datenveröffentlichung werden Unternehmensleiter unter der Führung von CEO Daniel Faga an zwei wichtigen Investorenkonferenzen teilnehmen: der Jefferies Global Healthcare Conference am 5. Juni und der Goldman Sachs Global Healthcare Conference am 11. Juni 2025.
- None.
- None.
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review updated data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Tuesday, June 3, 2025, at 4:15pm ET / 1:15pm PT.
During the webcast, members of Anaptys management will be joined by Paul Emery, M.D., professor, Rheumatology, University of Leeds, Leeds Biomedical Research Centre, U.K. and Jonathan Graf, M.D., professor of Medicine, Rheumatology, University of California, San Francisco and a RENOIR clinical trial investigator.
Additionally, Anaptys president and chief executive officer, Daniel Faga, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences following the data release:
Jefferies Global Healthcare Conference, New York, NY
- Format – Presentation and one-on-one investor meetings
- Date and Time – Thursday, June 5, 2025, at 8:45am ET / 5:45am PT
Goldman Sachs 46th Annual Global Healthcare Conference, Miami, FL
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Wednesday, June 11, 2025, at 8:40am ET / 5:40am PT
Live webcasts of the data release, as well as the presentation and fireside chat, will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events. Replays of the webcasts will be available for at least 30 days following the events.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. The company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulator, in Phase 1 trials. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com
FAQ
When will ANAB announce Phase 2b RENOIR trial results for rosnilimab?
What is rosnilimab being developed for by AnaptysBio?
Which key medical experts will present at ANAB's rosnilimab data presentation?
Which investor conferences will AnaptysBio attend after the rosnilimab data release?
